ISO 13485 Clause 8 Transition Notes
The QMSR eliminates FDA-specific structure in favor of ISO 13485:2016 clauses. All above ISO 13485 clauses are now explicit requirements under QMSR.
New documentation and risk-based decision-making are emphasized throughout the QMSR.
Clause 8.2.3 (Reporting to Regulatory Authorities) under ISO 13485 is aligned with external FDA regs, such as 21 CFR Parts 803 (MDR), 806 (Corrections and Removals), and 1004 (Repurchase/Replacement).
ISO 13485 Clause 8
Measurement, Analysis, and Improvement
The transition from the FDA’s Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR) marks a significant evolution in how medical device manufacturers are expected to approach quality assurance and regulatory compliance.
One of the most critical areas impacted by this transition is Clause 8 of ISO 13485:2016, which focuses on the processes of measurement, analysis, and improvement. This clause aligns with the QMSR’s increased emphasis on risk-based thinking, continuous monitoring, and feedback-driven improvement, making it central to both regulatory compliance and long-term product safety and effectiveness.
Available in paperback and eBook formats on Amazon.
Click on the image or this link to see the book on the Amazon website.